20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026

Management to Hold One-on-One Meetings with Institutional Investors at the Hard Rock Hotel New York

GAITHERSBURG, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that President and Chief Executive Officer Jonathan Cohen and Chief Financial Officer Alan Bergman will participate in the Maxim Growth Summit 2026, being held October 13 and 14, 2026 at the Hard Rock Hotel New York. The Summit’s healthcare program takes place Wednesday, October 14.

Mr. Cohen and Mr. Bergman will hold one-on-one meetings with institutional investors at the Summit and in additional meetings scheduled in New York that week.

Maxim Growth Summit 2026
Dates: October 13 and 14, 2026; healthcare program Wednesday, October 14
Location: Hard Rock Hotel New York, 159 West 48th Street, New York, NY 10036
Format: One-on-one investor meetings
Attendees: President and Chief Executive Officer Jonathan Cohen; Chief Financial Officer Alan Bergman
Conference Website: Click here

To schedule a one-on-one meeting with management at the Maxim Growth Summit or in New York that week, please contact your Maxim Group representative, email [email protected], or call Chris Tyson at (949) 491-8235.

About 20/20 BioLabs

20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest™ for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s affordable, accurate, accessible tests can be conveniently utilized at home using new, upper-arm capillary collection devices that avoid painful needles. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.

For more information visit https://2020biolabs.com.

Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
[email protected]

You May Also Be Interested In

• Crypto Update: Remittix Raises $33 Million, Prepares 41 New Fiat Currencies and Sets Earn to Go Live as Bitcoin and XRP Price Predictions Target $250,000 and $20
• AEVEX Reaffirms Maritime Systems Strategy and Continued U.S. Navy Investment
• QIAGEN reports preliminary Q3 2026 results